• 1
    Brinker BT,Krown SE,Lee JY, et al. Phase 1/2 trial of BMS-275291 in patients with HIV-related Kaposi sarcoma. A multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008; 112: 000000.
  • 2
    Di Lorenzo G,Di Trolio R,Montesarchio V, et al. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. Cancer. 2008; 112: 000000.
  • 3
    Pantanowitz L,Dezube BJ. Advances in the pathobiology and treatment of Kaposi sarcoma. Curr Opin Oncol. 2004; 16: 443449.
  • 4
    Douglas JL,Gustin JK,Dezube B,Pantanowitz JL,Moses AV. Kaposi's sarcoma: a model of both malignancy and chronic inflammation. Panminerva Med. 2007; 49: 119138.
  • 5
    Dezube BJ. The role of human immunodeficiency virus-I in the pathogenesis of acquired immunodeficiency syndrome-related Kaposi's sarcoma: the importance of an inflammatory and angiogenic milieu. Semin Oncol. 2000; 27: 420423.
  • 6
    Duprez R,Lacoste V,Briere J, et al. Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma. J Natl Cancer Inst. 2007; 99: 10861094.
  • 7
    Krown SE,Metroka C,Wernz JC. Kaposi's sarcoma in the acquired immune deficiency: a proposal for uniform evaluation, response and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989; 7: 12011207.
  • 8
    Nasti G,Talamini R,Antinori A, et al. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART Era—the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol. 2003; 21: 28762882.
  • 9
    Brambilla L,Boneschi V,Taglioni M,Ferrucci S. Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eur J Dermatol. 2003; 13: 8386.
  • 10
    Di Lorenzo G,Konstantinopoulos PA,Pantanowitz L,Di Trolio R,De Placido S,Dezube BJ. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol. 2007; 8: 167176.
  • 11
    Dezube BJ,Pantanowitz L,Aboulafia DM. Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read. 2004; 14: 236253.
  • 12
    Allen TM,Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol. 2004; 31( suppl 13): 515.
  • 13
    Di Trolio R,Di Lorenzo G,Delfino M,De Placido S. Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review. Int J Immunopathol Pharmacol. 2006; 19: 253263.
  • 14
    Koon H,Pantanowitz L,Dezube BJ. Antiangiogenic therapy for Kaposi's sarcoma. In: DavisDW, HerbstRS, AbbruzzeseJL, editors. Antiangiogenic cancer therapy. Boca Raton, Fla: CRC Press; 2007: 755783.
  • 15
    Pantanowitz L,Dezube BJ,Hernandez-Barrantes S,Tahan SR,Dabbous MK. Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol. 2006; 33: 793798.
  • 16
    Cianfrocca M,Cooley TP,Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 2002; 20: 153159.
  • 17
    Dezube BJ,Krown SE,Lee JY,Bauer KS,Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol. 2006; 24: 13891394.
  • 18
    Krown SE. Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematol Oncol Clin North Am. 2003; 17: 763783.
  • 19
    Kelloff GJ,Boone CW,Crowell JA,Steele VE,Lubet R,Doody LA. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J Cell Biochem Suppl. 1994; 19: 19.
  • 20
    Kaaya E,Castanos-Velez E,Heiden T, et al. Proliferation and apoptosis in the evolution of endemic and acquired immunodeficiency syndrome-related Kaposi's sarcoma. Med Oncol. 2000; 17: 325332.